Acorda Therapeutics, Inc. (ACORQ)
Aug 22, 2024 - ACORQ was delisted (reason: shares cancelled)
0.0100
0.00 (0.00%)
Inactive · Last trade price
on Aug 23, 2024
Acorda Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Year Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | NaN - NaN |
|---|---|---|---|---|---|---|
| Revenue | 117.63 | 118.57 | 129.07 | 152.97 | 192.41 | Upgrade
|
| Revenue Growth (YoY) | -0.79% | -8.14% | -15.62% | -20.50% | -59.19% | Upgrade
|
| Cost of Revenue | 20.44 | 35.84 | 50.61 | 56.18 | 93.53 | Upgrade
|
| Gross Profit | 97.2 | 82.73 | 78.46 | 96.79 | 98.88 | Upgrade
|
| Selling, General & Admin | 89.7 | 106.01 | 119 | 152.58 | 189.85 | Upgrade
|
| Other Operating Expenses | - | -12.55 | - | - | - | Upgrade
|
| Operating Expenses | 120.46 | 124.22 | 149.76 | 183.34 | 215.48 | Upgrade
|
| Operating Income | -23.26 | -41.49 | -71.3 | -86.55 | -116.61 | Upgrade
|
| Interest Expense | -31.53 | -30.2 | -30.04 | -30.57 | -21.87 | Upgrade
|
| Interest & Investment Income | 0.53 | 1.91 | 0.01 | 0.82 | 4.17 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.29 | -0.01 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0.05 | 1.29 | 1.15 | 40.13 | 0.01 | Upgrade
|
| EBT Excluding Unusual Items | -54.5 | -68.5 | -100.18 | -76.19 | -134.3 | Upgrade
|
| Merger & Restructuring Charges | - | -0.55 | -6 | -0.34 | -4.4 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -277.56 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.17 | - | - | -57.9 | - | Upgrade
|
| Asset Writedown | -251.32 | - | - | -4.13 | - | Upgrade
|
| Other Unusual Items | 9.63 | 33.8 | -2.9 | 30.89 | 142.01 | Upgrade
|
| Pretax Income | -296.02 | -35.25 | -109.07 | -107.67 | -274.25 | Upgrade
|
| Income Tax Expense | -43.17 | 30.67 | -5.12 | -8.07 | -1.28 | Upgrade
|
| Earnings From Continuing Operations | -252.85 | -65.92 | -103.95 | -99.59 | -272.97 | Upgrade
|
| Net Income | -252.85 | -65.92 | -103.95 | -99.59 | -272.97 | Upgrade
|
| Net Income to Common | -252.85 | -65.92 | -103.95 | -99.59 | -272.97 | Upgrade
|
| Shares Outstanding (Basic) | 1 | 1 | 1 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 1 | 1 | 1 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 22.85% | 90.38% | 31.38% | 1.98% | 0.47% | Upgrade
|
| EPS (Basic) | -203.59 | -65.20 | -195.75 | -246.40 | -688.70 | Upgrade
|
| EPS (Diluted) | -203.59 | -65.23 | -195.80 | -246.40 | -688.70 | Upgrade
|
| Free Cash Flow | -14.25 | -21.06 | -41.51 | -65.4 | -218.59 | Upgrade
|
| Free Cash Flow Per Share | -11.47 | -20.83 | -78.17 | -161.79 | -551.52 | Upgrade
|
| Gross Margin | 82.63% | 69.78% | 60.79% | 63.27% | 51.39% | Upgrade
|
| Operating Margin | -19.78% | -34.99% | -55.24% | -56.58% | -60.60% | Upgrade
|
| Profit Margin | -214.95% | -55.59% | -80.54% | -65.11% | -141.87% | Upgrade
|
| Free Cash Flow Margin | -12.11% | -17.76% | -32.16% | -42.75% | -113.61% | Upgrade
|
| EBITDA | 8.4 | -8.68 | -37.65 | -45.66 | -82.63 | Upgrade
|
| EBITDA Margin | 7.14% | -7.32% | -29.17% | -29.85% | -42.95% | Upgrade
|
| D&A For EBITDA | 31.67 | 32.81 | 33.65 | 40.9 | 33.97 | Upgrade
|
| EBIT | -23.26 | -41.49 | -71.3 | -86.55 | -116.61 | Upgrade
|
| EBIT Margin | -19.78% | -34.99% | -55.24% | -56.58% | -60.60% | Upgrade
|
| Revenue as Reported | 117.63 | 118.57 | 129.07 | 152.97 | 192.41 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.